CellCept®

DRUG4 trials

Sponsors

Teva Pharmaceuticals USA, University of Saskatchewan

Conditions

Cardiovascular DiseaseCardiovascular OutcomesHealthyKidney Transplant RecipientsKidney Transplantation

Phase 1

Mycophenolate Mofetil Tablets Under Fed Conditions

CompletedNCT00908128

Teva Pharmaceuticals USAHealthy

Start: 2006-08-31End: 2006-08-31Updated: 2024-08-19

Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

CompletedNCT00910663

Teva Pharmaceuticals USAHealthy

Start: 2006-10-31End: 2006-11-30Updated: 2024-08-19

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

CompletedNCT00911274

Teva Pharmaceuticals USAHealthy

Start: 2006-10-31End: 2006-11-30Updated: 2024-08-19

Phase 4

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

WithdrawnNCT02058875

University of SaskatchewanCardiovascular Disease, Cardiovascular Outcomes, Kidney Transplantation +1

Start: 2014-02-28End: 2015-10-31Updated: 2017-01-09